Login to Your Account



Progenics Offering Pulls Down $48.9M For Opioid Antagonist

By Randall Osborne


Monday, November 17, 2003
With Phase III data from its product candidate for opiate-induced constipation expected by year's end, Progenics Pharmaceuticals Inc. priced a public offering of 3.25 million shares at $16.25 each, for net proceeds of about $48.9 million. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription